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Running title: Proteome of mimetic-nanovesicles 
ABSTRACT  
 
Cargo sorting of selective biomolecules and relatively low quantities of extracellular vesicles (EVs) 
produced by cells present challenges when upscaling EV production for therapeutic use. These issues 
may be overcome through producing artificial EVs. Cell-derived mimetic nanovesicles (M-NVs) are a 
potentially promising alternative to EVs for clinical applicability, demonstrating cost-effectiveness 
and higher yield without incumbent production and isolation issues. Although several studies have 
shown that M-NVs have similar morphology, size and therapeutic potential compared to exosomes, 
comprehensive characterization and to what extent M-NVs components mimic exosomes remain 
elusive. We generated M-NVs through the extrusion of cells and performed proteomic profiling 
which defined proteins associated with membrane and cytosolic components. In this context, our 
proteomic data reveal a subset of proteins that are highly abundant in M-NVs in comparison to 
exosomes. M-NVs contain proteins that largely represent the parental cell proteome, whereas the 
profile of exosomal proteins highlight their endosomally derived origin. This advantage of M-NVs 
alleviates the necessity of endosomal sorting of endogenous therapeutic proteins or RNA into 
exosomes. Our study also highlights differences in protein post-translational modifications among M-
NVs, as distinct from exosomes, using a non-targeted informatic approach, specifically showing 
phosphorylation, ubiquitination, and thiophosphorylation as enriched protein modifications in M-
NVs. Overall this study provides key insights into defining the proteome composition of M-NVs as a 
distinct from exosomes, and the potential advantage of M-NVs as an alternative nanocarrier when 
spontaneous endosomal sorting of therapeutics are limited.  
www.proteomics-journal.com Page 3 Proteomics 
 
 
This article is protected by copyright. All rights reserved. 
 
1 INTRODUCTION 
 
Exosomes are cell-derived extracellular vesicles (EVs) of endosomal origin that are naturally released 
by most cells and are fundamental for intercellular communication 
[1]
. Exosomes are produced 
through further modification and enrichment at multi-vesicular bodies (MVBs), resulting in 
enrichment of proteins associated with the endosomal pathway. They have the ability to transport 
endogenous biological cargo, such as small RNAs, mRNAs and proteins across neighboring and 
distant cells. This feature of exosomes as natural mediators of intercellular communication opens the 
avenue for utilizing them as a therapeutic delivery system. Many researchers have manipulated the 
architecture of  exosomes by genetically engineering specific proteins or peptides to further enhance 
therapeutic efficiency 
[2]
. Exosomes offer significant advantages over conventional lipid-based 
delivery systems including biocompatibility, stability, low immunogenicity and innate ability to target 
and interact with recipient cells. However, translation to clinical applications has been limited by 
several factors such as heterogeneity, cargo sorting, therapeutic loading, large-scale manufacture, low 
yield, storage, cost and multi-step approaches in isolation and purification 
[3-9]
. To address these 
challenges an alternative approach has been employed to generate an artificial vesicle to mimic EVs 
(mainly exosomes ) by morphology, size and potentially in vitro and in vivo behavior. Cell-derived 
mimetic nanovesicles (M-NVs) are an emerging and potentially promising alternative to exosomes for 
clinical applicability, demonstrating reproducibility in protocol, cost-effectiveness and higher yield 
production rates. The benefits of M-NVs address issues of relatively low quantities of  exosomes 
produced by cells and the involvement of extensive isolation and purification procedures 
[10-14]
. 
Importantly, the biological activity and uptake of M-NVs was confirmed in vitro using cellular uptake 
studies and in vivo biodistribution studies. Similar to exosomes, proteins on the surface of M-NVs 
may be involved in signaling and ultimately the fate of vesicles. The membrane proteins found on M-
NVs were shown to be important in the efficient delivery of doxorubicin as trypsinization of M-NVs 
imped their function. This suggests that membrane proteins found on the surface of M-NVs play a 
crucial role in vesicle uptake 
[13]
.  
 
M-NVs can be loaded with therapeutics by genetically engineering the cell or exogenously using 
electroporation or during the extrusion of cells 
[11, 15]
. M-NVs generated from monocytes or 
macrophages exogenously loaded with a chemotherapeutic compound by electroporation was shown 
to be successfully delivered in vivo to malignant tumors 
[13]
 and demonstrated comparable delivery 
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efficiency to  exosomes. Unlike exosomes, which requires selective sorting of cargo through the 
endosomal pathway, it’s feasible to engineer cells to overexpress cytosolic or membrane proteins or 
RNA and subsequently generate M-NVs. For example, expressing a shRNA of interest into a parental 
cell line was shown to produce M-NVs packaged with siRNA that could knock down c-Myc 
[11]
. A 
recent study demonstrated successful packaging of Lnc-RNA-H19 into M-NVs targeted for wound 
healing in diabetics through expressing Lnc-RNA-H19 in parental cells 
[15]
. Other examples in the 
literature include packaging M-NVs with paclitaxel during the extrusion process that was used to 
deliver anti-cancer drugs to target cells 
[16]
.  M-NVs derived from murine pancreatic β-cell line were 
able to differentiate therapeutic insulin producing cells providing a cell free therapeutic approach 
[12]
. 
The regenerative capability of M-NVs may be useful in replacing cell-based therapeutics where the 
targeted tissues may require enhanced potency which could be further enriched within M-NVs.  
 
Although the therapeutic potential of M-NVs has been demonstrated, the proteome cargo of M-NVs 
has not been comprehensively characterized and it is unknown to what extend their cargo could mimic 
the proteome of natural  exosomes. Furthermore, it is imperative to comprehensively characterize 
their composition as their contents may potentially have an effect on recipient cells. In this study, we 
investigated the proteome of M-NVs that can be produced through the extrusion of cells and 
compared the profiles to exosomes secreted from the same cell line. We report a subset of proteins 
highly abundant in M-NVs in comparison to well-known exosomal cargo proteins. Given the 
importance of protein modifications in exosome biology, we further investigated the protein post-
translational modification (PTMs) profile among M-NVs and exosomes using a non-targeted 
informatic approach, highlighting unique differences in M-NVs. Using M-NVs would address current 
challenges faced with efficient loading of therapeutics to exosomes. Collectively, this study provides 
key insights into defining the proteome composition of M-NVs as distinct from  exosomes, and 
further understanding of the emerging potential of M-NVs as an alternative nanocarrier modality for 
loading therapeutics which are not naturally sorted into  exosomes.  
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2 MATERIALS AND METHODS  
 
2.1 Cell culture 
Human neuroblastoma SH-SY5Y cells were purchased from American Type Culture Collection 
(ATCC). To generate M-NVs, SH-SY5Y cells were maintained in complete Dulbecco’s Modified 
Eagle Medium (DMEM; Invitrogen) supplemented with 10% (v/v) heat inactivated fetal calf serum 
(FCS; Invitrogen) and 5% (v/v) GlutaMAX
TM 
(Invitrogen) which were incubated at 37° C in 5% CO2. 
For exosome isolation, cells were grown to ~90% confluency and passaged by resuspending in 10% 
exosome-depleted FCS (ultracentrifuged at 100,000 g for 16 h at 4° C) DMEM and left to culture at 
37° C with 5% CO2 for 48 h. 
 
2.2 Exosome isolation by differential ultracentrifugation 
Exosome isolation from conditioned media was performed using differential ultracentrifugation as 
previously described 
[17]
. Briefly, culture medium (CM) (120 mL from approximately 1.2  10
8
 cells )  
was harvested and centrifuged (2,000 g, 10 min) to sediment dead cells and remove cellular debris.  
CM was centrifuged at 10,000 g for 30 min to remove large microvesicles. The resultant supernatant 
was ultracentrifuged at 100,000 g for 70 min at 4° C  to pellet  exosomes. The exosome pellet was 
resuspended in 1 mL filtered (0.2 μm) DPBS (Dulbecco’s Phosphate-Buffered Saline, Invitrogen), 
and centrifuged at 100,000 g for 70 min at 4° C and resuspended in DPBS. 
 
2.3 M-NVs generation and purification  
SH-SY5Y cell-derived mimetic nanovesicles (M-NVs) were generated by a Mini-Extruder system 
(Avanti Polar Lipids) following a previously published protocol 
[13]
. Cells (~90% confluency, 1.2 × 
10
8
 cells) were harvested and re-suspended in filtered DPBS. M-NVs were generated from a 
suspension of cells through sequential filtration using polycarbonate track-etched membranes of 10 
μm, 5 μm and 1 μm filters (Whatman membrane filter, Merck) which involved passing the suspension 
13 times across each filter. The extruded M-NVs were subsequently purified using OptiPrep™ density 
gradient. Briefly, to prepare the discontinuous iodixanol gradient, 50% (w/v) and 10% (w/v) solutions 
of iodixanol were made by diluting a stock solution of OptiPrep™ (60% (w/v) aqueous iodixanol 
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from Axis-Shield PoC, Norway) with 10X NTE buffer (100 mM Tris, 10 mM EDTA and 1.37 M 
NaCl, pH 7.4). The gradient was formed by adding 1 mL of 50% (v/v) iodixanol solution to a 14  89 
mm polyallomer tube (Microfuge
®
 Tube, Beckman Coulter), followed by careful layering of 1 mL 
10% (v/v) solution. For M-NV purification, extruded vesicles (5 mL) were overlaid on the gradient, 
followed by centrifugation at 100,000 g (45 Ti rotor; Beckman Coulter-Optima XPN-100) for 2 h at 
4° C. Seven individual fractions were collected manually (with increasing density) and Coomassie 
Brilliant Blue R-250 stain used to determine protein abundance on samples resolved using SDS-
PAGE. Here, samples were loaded on 4-12 % Bis-Tris SDS-PAGE protein gel (Invitrogen) and 
resolved at 120 V for 1 h and 20 min. The SDS-PAGE gel was removed from the electrophoresis tank 
and stained with Coomassie blue stain (10% (v/v) acetic acid, 40% (v/v) methanol and 0.1% (w/v) 
Coomassie Brilliant Blue R-250 (Sigma-Aldrich) and heated in the microwave for 45 s. The gel was 
then incubated for 5 min at room temperature on a shaker followed by destaining buffer (10% (v/v) 
acetic acid, 20% (v/v) methanol) and heated in the microwave for 45 s. Images were taken by 
ChemiDoc™ Touch Imaging System (Bio-Rad). The protein content of exosomes and M-NVs 
preparations was estimated by Pierce™ BCA protein assay kit (ThermoFisher). 
 
2.4      Western immunoblotting 
Following SDS-PAGE, proteins were transferred to a 0.45μm polyvinylidene fluoride (PVDF) 
membrane using Bio-Rad western transfer apparatus in transfer buffer (25 mM Tris, 200 mM glycine, 
20% (v/v) methanol) at 100 V for 50 min. The membrane was then blocked with 5 % (w/v) skim milk 
and incubated with primary antibodies overnight at 4° C . Membranes were washed and probed with 
secondary antibody for 1 h at room temperature. The blot was developed by Clarity
TM 
ECL reagent 
(Bio-Rad) according to the manufacturer’s protocol. The membranes were imaged by ChemiDoc 
Touch imaging system (Bio-Rad) and further analyzed by Image Lab Software (Bio-Rad). Primary 
antibodies used for western blot analysis were TSG101 (Abcam), Flotillin (BD Bioscience), Bcl2 (BD 
Bioscience), Actin (Cell Signaling Technology) and Mouse secondary antibody (GE Healthcare). 
 
2.5 Silver staining 
Gel-based protein profiles for cell lysate, exosomes and M-NVs was assessed using silver staining 
(SilverQuest
TM 
Silver staining kit, Invitrogen). Samples were loaded on 4-12 % Bis-Tris SDS-PAGE 
www.proteomics-journal.com Page 7 Proteomics 
 
 
This article is protected by copyright. All rights reserved. 
 
protein gel (Invitrogen) and resolved at 120V for 1 h and 20 min. The gel was gently rinsed with 
ultrapure water and stained according to the manufacturer’s protocol.  
 
2.6 Nanoparticle tracking analysis  
Particle size and concentration were measured by NanoSight NS300 (Malvern Panalytical). Samples 
were diluted with DPBS, loaded in a 1 mL syringe and analyzed with the infusion rate of 50. The 
movement of particles through the flow cell was recorded for 30 s and five technical replicates 
performed. Analysis was carried out by the NanoSight NS300 NTA software (NTA 3.2). Four 
biological replicates were performed for both vesicle types. 
 
2.7 Transmission electron microscopy  
Heavy carbon-coated formvar copper grids (ProSciTech, SA, Australia) were glow discharged and 
incubated with an aliquot of exosomes and M-NVs for 15 min at room temperature. Grids were 
washed with ultra-pure water and negatively stained with 2.5 % (v/v) uranyl acetate (Agar Scientific). 
Excess solution was blotted off immediately and samples were allowed to dry for 15 min prior to 
imaging. Electron microscopy (EM) images were taken using a Jeol JEM-2100 instrument.  
 
2.8 Mass spectrometry-based proteomics  
M-NVs, exosomes, and cell lysates were prepared for proteome profiling as described 
[18]
. Briefly,  M-
NVs (20 g) and exosomes (20 g), were lysed in 100 mM triethylammonium bicarbonate in 0.1% 
Rapigest (Waters, Milford, MA) with 2 min sonication and incubation at 95 °C for 5 min. Cell lysates 
(20 g) were lysed in 0.5% sodium deoxycholate in 100 mM triethylammonium and incubation at 95° 
C for 5 min. Samples were reduced with 12.5 mM tris(2-carboxyethyl)phosphine hydrochloride 
(Sigma-Aldrich, C4706) at 28° C for 4 h with gentle rotation, alkylated with 12.5 mM 
chloroacetamide (Sigma-Aldrich) for 30 min at 37° C, and digested with 2 μg bovine sequencing 
grade trypsin (Promega, V5111) at 37° C for 18 h.  For cell lysate samples, sodium deoxycholate was 
removed following digestion as previously described 
[19]
. Subsequently, peptides were purified and 
extracted using reverse-phase C18 StageTips (Sep-Park cartridges, Waters, MA) in 85% (v/v) 
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acetonitrile (ACN) in 0.5% (v/v) formic acid (FA). Peptides were lyophilized and acidified with 
buffer containing 0.1% FA, 2% ACN.  
 
Proteomic experiments were performed in biological quadruplicates (N=4), with technical replicates 
(N=3), with MIAPE-compliance 
[20, 21]
. A peptide pool was made group-wise using 2 µl from each 
sample. Samples were then analyzed per LC-MS analysis, in random and duplicates of the pooled 
sample distributed, so a pool was analyzed every seventh run. A nanoflow UPLC instrument 
(Ultimate 3000 RSLCnano, Thermo Fisher Scientific) was coupled on-line to a Q-Exactive HF 
Orbitrap mass spectrometer (Thermo Fisher Scientific) with a nanoelectrospray ion source (Thermo 
Fisher Scientific). Peptides were loaded (Acclaim PepMap100, 5 mm × 300 μm i.d., μ-Precolumn 
packed with 5 μm C18 beads, Thermo Fisher Scientific) and separated (Acclaim PepMap RSLC C18 
column 1.9 μm 120Å, 360/75 μm × 750 mm, Thermo Fisher Scientific) with a 60 min gradient (M-
NVs/exosomes) and 90 min gradient (cell lysates) from 4-50% (v/v) phase B (0.1% (v/v) FA in 80% 
(v/v) ACN) (4–10% from 0–10 min, 10–50% from 10–60 min (M-NVs/exosomes) and 10-90 min 
(cell lysates) at a flow rate of 300 nL/min operated at 60° C .  
 
The mass spectrometer was operated in positive, data-dependent mode where the top 6 most abundant 
precursor ions in the survey scan (350–1500 m/z) (standard sample) and top 15 most abundant 
precursor ions in the survey scan (350–1500 m/z) (pooled sample) was used for MS/MS 
fragmentation. Survey scans were acquired at a resolution of 60,000 with MS/MS resolution of 
15,000. Unassigned precursor ion charge states and singly charged species were rejected and peptide 
match disabled. The isolation window was set to 1.6 Da and selected precursors fragmented by HCD 
with normalized collision energies of 27 with a maximum ion injection time of 110 msec. Ion target 
values were set to 3e6 and 1e5 for survey and MS/MS scans, respectively. Dynamic exclusion was 
activated for 6 sec. Data was acquired using Xcalibur software v4.0 and Tune 2.9 (Thermo Fisher 
Scientific). Raw mass spectrometry data is deposited in the ProteomeXchange Consortium via the 
PRIDE partner repository with the dataset identifier 
[22]
 
 
2.9 Database searching and protein identification 
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For protein identification, the MS raw-files of the samples and pooled samples were searched in 
MaxQuant 
[23]
;v1.5.8.3 using standard setting including match-between-runs against UP000005640 
Homo sapiens (Uniprot proteome reference; 2/22/2017, 20.347 proteins) and reversed database for 
FDR investigation. Cell lysates were searched independently from the M-NV and exosomes samples. 
Peptide lists were generated from a tryptic digestion with up to two missed cleavages, cysteine 
carbamidomethylation as fixed modification, and methionine oxidation and protein N-terminal 
acetylation as variable modifications. Data was analyzed with a parent tolerance of 4.5 ppm, fragment 
tolerance of 20 ppm and minimum peptide length 7, with false discovery rate 1% at the peptide and 
protein levels, and with label-free quantitation (LFQ) 
[24]
. The output was processed using R 
Programme. Reverse identifications were excluded, and non-zero quantitation values required in more 
than half of each sample group for further processing.  
 
LFQ data was filtered for two or more unique peptides and log2-transformed.  Principle component 
analysis (PCA)  including all sample groups was performed, where multivariate imputation by 
chained equations using predictive mean matching was used for missing values 
[25]
. Relative 
quantification comparison between M-NV and exosomes was performed in R, where all data were 
included and filtered. Technical replicates were averaged and hierarchical clustering analyses (HCA) 
performed, missing values computations performed as described. For differential expression analyses 
between groups, unpaired two-tailed t-tests and resulting p-values were adjusted by the Benjamini-
Hochberg multi-test adjustment method for a high number of comparisons 
[26]
 and statistics performed 
as previously described 
[18, 21]
. For gene ontology (GO) enrichment and pathway analyses, FunRich 
[27]
; v3.1.3, Kyoto Encyclopedia of Genes and Genomes (KEGG) and NIH Database for Annotation, 
Visualization and Integrated Discovery Bioinformatics Resources 6.7 (DAVID) resources were 
utilized using recommended analytical parameters 
[28]
. For gene ontology enrichment and network 
analyses UniProt (www.uniprot.org) database resource (biological process, molecular function) was 
utilized. 
 
2.10 Protein post-translational modifications identification and quantitation data analysis 
To identify global PTMs differences raw data (M-NVs/exosomes) was searched using PEAKS (
[29]
; 
v8.5) against the UP000005640 Homo sapiens Uniprot database. Initially, for protein and PTM 
identifications, all standard settings were employed with carbamidomethyl (C) as a static modification 
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and oxidation (M) as variable modifications. The most abundant modification was then searched 
separately in database searches as variable modifications to ensure full coverages. All modifications 
were restricted to a false discovery rate 1% at the peptide and protein levels and annotation score (A) 
> 20 
[29]
. LFQ modification outputs were combined and processed as described using R, with 
contaminants, and reverse identification excluded from further data analysis. LFQ ratio between 
modified and unmodified peptides was calculated and log2 transformed as well as non-zero 
quantitation value in more than half of the samples was required for further analysis. Resulting p-
values were adjusted by the Benjamini-Hochberg multi-test adjustment method for a high number of 
comparisons 
[26]
 and statistics performed as previously described 
[30]
. HCA analysis was made on the 
averaged technical replicates, and missing values was dealt with using same procedure as the data-
dependent proteome profiling protein identification. Significant differences between the two groups 
were found using the same procedure as for the protein quantification data. Proteins with significant 
regulated PTMs corresponding to a 2-fold change and adjusted p-value of <0.05 was cross validated 
for identification with a MaxQuant PTM search of the top 11 modifications, a MaxQuant Dependent 
peptide search and a literature search. Six MaxQuant searches was performed with the different 
modifications as variable modifications: 1: Acetylation (N-term) and Deamidation (NQ) 2: 
Dimethylation(KR) and Methylation(KR) 3: methionine oxidation and Sulfation 4: Phosphorylation 
(STY) 5: Pyro-glu from E, Pyro-glu from Q 6: Carbamylation and Ubiquitination. Otherwise the same 
settings as mentioned earlier was applied. Same setting was used in MaxQuant Dependent peptide 
with oxidation as variable modification and Dependent peptide search FDR set to 0.01 together with a 
mass bin size of 0.0065 Dalton.   
 
3 RESULTS AND DISCUSSION  
In this study, we generated M-NVs by extruding human neuroblastoma SH-SY5Y cells which were 
then characterized for EV markers and directly compared to SH-SY5Y exosomes. Label-free 
proteomics was then performed to investigate the proteome between M-NVs and exosomes to provide 
an insight into what extent M-NVs mimic the proteome of biological exosomes. 
 
3.1 Production of Cell-derived M-NVs and Isolation of exosomes  
To obtain cell-derived M-NVs and exosomes, SH-SY5Y cells were harvested to generate M-NVs, 
while exosomes were isolated from the conditioned supernatant (Figure 1). For M-NVs, cells (1.2 × 
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10
8
) were serially extruded through a series of polycarbonate membranes with pore sizes of 10, 5, and 
1 μm to generate crude M-NVs (Figure 1A). The extruded vesicles were further purified based on 
two-step OptiPrep density-gradient ultracentrifugation (10 and 50% (v/v) iodixanol) to remove 
aggregates and heterogenous particles. M-NVs were found enriched in fraction 6 (F6) at the interface 
of the iodixanol layer. Exosomes were isolated from cell conditioned medium by differential 
ultracentrifugation and used for subsequent analysis (Figure 1B). In order to isolate a sufficient yield 
of exosomes, a large quantity of cells is required, which involves upscaling cultures for a minimum of 
2-3 passages, in addition to an incubation phase of 48 h. Furthermore, exosomes must be depleted 
from FCS to avoid cross-species contamination of FCS-derived exosomes in the conditioned 
supernatant. In contrast, generation of M-NVs only requires one passage of cell culture, does not 
require incubation of exosome-depleted FCS thus, providing a highly efficient system (minimum ~3-4 
days saved).  
 
3.2 Characterization of Mimetic NVs and exosomes 
Nanoparticle tracking analysis of the purified M-NVs showed a size distribution and a mode of ~186 
nm, comparable to that of exosomes (mode ~179 nm) from SH-SY5Y cells (Figure 2A). The 
morphology and shape of purified M-NVs and exosomes was examined using EM to reveal that they 
were enclosed with a lipid membrane, round cup-shaped vesicles and the preparations were devoid of 
the parent cells and cellular debris (Figure 2B). We observed that from the same number of cells (1.2 
 10
8
) cultured for 24 h, M-NVs produced 3,615 g of total protein and 5.3  10
11
 particles which was 
significantly more compared to exosomes which produced 83.5 g of total protein and 4.7  10
9
 
particles (Figure 2C). Producing M-NVs through serial extrusion increased the yield of total protein 
by more than 40-fold (average) and particle number more than 100-fold higher (average) than that of 
naturally produced exosomes from the same parental cells. The results demonstrated here show that 
producing M-NVs is highly reproducible and allows for large scale production of vesicles as 
published previously by other groups 
[11-13]
.  
 
A challenge in using exosomes as therapeutic delivery system is the lack of standardization for 
quantification. Currently, a common method for quantification of exosomes is based on cell 
equivalent or total particles count which is not a definite representation of homogeneity and particle 
yield. While, the quantification of M-NVs could be reflected by an actual count of particles generated. 
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In addition, the quantity and composition of exosomes can be influenced by variations in cell 
physiological behavior. Cell cultures need to be controlled during every passage to ensure that they do 
not alter the cargo of exosomes and therapeutic potency 
[31]
. The advantages of using cell-derived M-
NVs allows for a larger scale production of vesicles from a continuously maintained cell system that 
is not limited by alterations in cell biology.  
 
3.3 Proteomic profiling reveals distinct protein landscape in M-NVs 
To gain insights into the proteome of M-NVs and how their contents compare to the parental cell and 
biological exosomes, we performed label-free mass spectrometry-based proteomics. Protein 
visualization using Silver Protein Stain indicates differences in M-NVs in comparison to exosomes 
and parental cells (Figure 3A). Furthermore, we validated and compared the expression of exosomal 
enriched proteins in M-NVs (Figure 3B). TSG101, a protein involved in exosomes biogenesis, is 
known to be highly enriched in exosomes as seen in Figure 3B. Interestingly, we found that M-NVs 
do not abundantly package TSG101 which was found to be similar to parental cells. However, 
flotillin, a membrane associated protein, is found equally expressed in all samples. The expression of 
membrane associated proteins such as tetraspanins (CD63, CD9 and CD81) have also been found in 
M-NVs 
[12, 13]
 which highlights that the ultrastructure of parental cells and potentially exosomes are 
conserved at the membrane of M-NVs. Next, we investigated the expression of proteins which are 
globally present in cells but not selectively sorted into exosomes. While Bcl2 is regarded as a negative 
marker for exosomes 
[32, 33]
, M-NVs were found to contain an abundant amount of Bcl2 protein 
(Figure 3B). Because the overexpression of Bcl2 has been shown to protect immortalized cells from 
chemically-induced cell death 
[34]
 and together with previous studies reporting a low abundance of the 
apoptotic inducer, Cytochrome C, in M-NVs 
[16]
, it is intriguing to speculate that M-NVs could be 
useful as potential anti-apoptotic agents. Overall, M-NVs can mimic the ultrastructure of exosomes 
but do not display an abundance of proteins that are typically involved in exosomes biogenesis. 
 
Proteomic profiling identified a total of 2,454 proteins from M-NVs, 2,141 proteins from exosomes, 
and 4,073 proteins from parental cells. A number of proteins (1,887) were commonly found in all 
samples (Figure 3C and Supplementary Table 1). Importantly, 19, 65 and 1,673 unique proteins 
were identified in M-NVs, exosomes and cells, respectively, indicating the enrichment of distinct 
proteins in M-NVs and exosomes (Figure 3C and Supplementary Table 1). To gain insight into the 
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potential functions of the enriched proteins in M-NVs, we conducted DAVID Functional Enrichment 
analysis based on GO and Kyoto Encyclopedia of Genes and Genomes (KEGG). Most proteins 
uniquely found in M-NVs, were associated with membrane protein and transcription factor GO terms. 
Proteins found to be exclusive to exosomes were associated with cell adhesion, protein lipid assembly 
and cytoskeletal protein binding. Interestingly, among 65 unique proteins found in exosomes, we 
report subsets of proteins (AKT3, DNAJC25, MOSPD2, RNASEH2B, SAT1, SRGAP2B, TECPR2 
and TLR8) which has not been identified previously in exosomes (ExoCarta).  
 
Variance within samples was demonstrated in an unsupervised Principal Component Analysis (PCA) 
(Figure 3D), indicating low variance between biological/technical replicates, and a distinct separation 
between exosomes, M-NVs, and cells. Importantly, the predominant variance in the proteome 
landscape is derived from differences between M-NVs and exosomes. 
 
3.4 M-NVs proteome is distinct from exosomes  
To gain insights into the proteome of M-NVs and how this compares to exosomes isolated from the 
same cell line, we examined the expression profile of each subset using differential expression based 
on label free quantification (LFQ). A total of 2,502 proteins were quantifiable in M-NVs and 
exosomes samples after strict filtering. Variance in protein abundance profiles was compared using 
Hierarchical clustering (Figure 4A), representing a distribution of differentially and similarly 
expressed proteins in M-NVs and exosomes. Differential protein expression between samples was 
examined by LFQ, student’s t-test and the resulting p-values corrected for multiple testing using the 
Benjamini-Hochberg procedure, indicating 1,664 proteins were significantly differentially expressed 
(FC>2, p<0.05) (Figure 4B). Importantly, this differentially regulated protein subset is more than 
65% of the quantifiable proteome, highlighting the different origin and composition of cell/plasma 
membrane-enriched M-NVs in comparison to endosomally-derived exosomes 
[35]
 . More specifically, 
when comparing biological and functional significance of these alterations in the proteome profiles 
between M-NVs and exosomes based on GO analyses, changes in translation, RNA processing, 
mRNA splicing, mitochondrial function, and protein transport to membrane were salient changes in 
M-NVs (Figure 4C). MAPK signalling and functions associated with cell proliferation and protein 
folding, in addition PTMs were enriched in exosomes, and support the known literature of these 
components associated with exosomes biology 
[36-38]
. 
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To identify enriched proteins present in M-NVs and exosomes, we performed statistical analysis on 
the expression levels of proteins identified in these data sets. We demonstrated 28 significantly 
enriched proteins in exosomes and 33 significantly enriched proteins in M-NVs (Figure 5). Among 
the exosomes-enriched conventional markers were proteins involved in the Endosomal Sorting 
Complex Required for Transport (ESCRT) machinery such as TSG101 
[39, 40]
 vacuolar protein-sorting 
proteins (VPS4B/13C/28/37B), multivesicular body proteins (CHMP1A/2A/4B/5), proteins involved 
in co-ordination of intracellular vesicle trafficking (e.g.,  tetraspanins such as CD9, CD81
[41, 42]
 and 
small Rab GTPases such as RAB27B and RAB35 
[43, 44]
 ) and annexins (ANXA5, ANXA6 
[45]
) 
(Figure 5). The total number of proteins enriched in exosomes associated pathways was indeed, 
mostly derived from the exosomes samples (59.6%, Figure 5) compared to M-NVs (40.4%, Figure 
5). This also demonstrates that although M-NVs are not endosomally derived vesicles, to some extend 
they are enriched in proteins associated with exosomes biogenesis. Of the significantly enriched 
proteins in M-NVs (57.3% in M-NVs compared to 42.7% in exosomes , Figure 5), integral 
component of membrane (SLC25A4/10/11/13/24, MTCH2, COX4I1, CPT1A, NNT, SFXN3), various 
NADH dehydrogenase members (NDUFA4/5/10/13, NDUFB9, NDUFS1/2/3/8, and NDUFV1/2) and 
mitochondrial membrane (SDHB and SFXN1) were identified (Figure 5). This finding suggests that 
significantly upregulated proteins in M-NVs were associated with mitochondrial proteins.  A salient 
finding were several protein translocases, involved in protein transport through plasma and 
mitochondrial membranes, including mitochondrial import receptor subunit TOM22 (TOMM22) and 
ADP/ATP translocase 1 (SLC25A4). Several proteins were found to be detected at similar expression 
levels within M-NVs and exosomes. These shared categories were associated with different pathways 
and organelles, including: DNA binding (MCM3, MCM4, MCM5 and RECQL), GTP binding 
(GTPBP1), RNA binding (DDX1/6/39A, PCBP1/2, AIMP1, MARS), mRNA processing (XRN2 and 
PRPF40A), proteins associated with nucleus (CDK1, KPNA2 and POLR2B) and ribosomal proteins 
(RPS6/20/23/26 and HNRNPH2). This finding indicates that despite unique packaging of cargos in 
each vesicle, subsets of proteins in M-NVs and exosomes were found to be expressed at a similar 
level. 
 
Next, we examined the most abundantly detected proteins in M-NVs. These include mitochondrial 
membrane proteins (ATP synthases ATP5H/5I/5J, ATPG/K), proteins involved in mitochondrial 
electron transport (COX5A/5B/41), mitochondrial import (TOM70/TOM22, sideroflexins SFXN1 and 
SFXN3, MTCH2, and MIRO2), various translocase (ADT1), dehydrogenase (SDHA/B) and synthase 
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enzymes associated with membrane organisation were ranked as the most abundant top 100 proteins 
(in comparison to exosomes ) (Supplementary Table 1). An abundance of NADH dehydrogenase 
members (NDUA4/5/9, NDUB9, NDUAA/AD, NDUBA, NDUS1/2/3/8, and NDUV1/2) were also 
found, associated with mitochondrial membrane. Interestingly, Lamina-associated polypeptide 2 
members (LAP2A/2B) were also relatively enriched which are important in nuclear transport and 
organisation, in addition to RNA-binding proteins RBM14, RBM28, and RBMX. 
 
Surface proteins on EVs play a fundamental role in intercellular behavior therefore, we further mined 
these proteomic data sets for known cell surface and plasma membrane components. We report 158 
cell surface, plasma membrane and plasma membrane-associated proteins (Supplementary Table 2). 
These include sodium/potassium-transporting ATPases ATP1A1/A3/B1/B3, plasma membrane-
associated small GTPase CDC42 and RALA, paralemmin-1 (PALM) that are involved in plasma 
membrane dynamics and cell process formation, long-chain fatty acid transport protein 4 (SLC27A4) 
involved in translocation across the plasma membrane, and phospholipid-transporting ATPase IA 
(ATP8A1) important in maintenance of asymmetric distribution of the phospholipid bilayer.  Further, 
various integrin components were identified in M-NVs including ITGA1/2/V/6, and ITGB1, and 
several cell surface receptor proteins were identified, including clusterin (CLU), CD151 and CD63 
antigens, myelin protein zero-like protein 1 (MPZL1), plexin-B2 (PLXNB2), and neutral amino acid 
transporter B(0) (SLC1A5). In addition, various connections between the cytoskeletal network and 
plasma membrane were identified, including Talin-1 (TLN1) Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1 (SLC9A3R1), and Ezrin (EZR). Overall, M-NVs contain an abundance of 
components associated with plasma membrane localization and regulation. These results confirmed 
that cell-derived M-NVs contain similar, yet distinct protein cargo to exosomes.  
 
In addition to select categories associated with metabolic pathways, mitochondrial function, and 
integral component of membrane, we observed an enrichment of protein modifications for 88 
proteins, including acetylation, phosphoprotein, oxidative phosphorylation, methylation, ubiquinone, 
and oxidative phosphorylation. Collectively, the bioinformatic analysis of the proteomic content of 
M-NVs and exosomes revealed potential PTMs that may also be different between M-NVs and 
exosomes.  
 
www.proteomics-journal.com Page 16 Proteomics 
 
 
This article is protected by copyright. All rights reserved. 
 
3.5 Distinct protein modification profiles of M-NVs and exosomes  
Based on significant enrichment of protein modification pathways in M-NVs, and the important role 
protein modifications play in EV biology, including their roles in exosomes cargo sorting and 
trafficking 
[37, 38]
, we performed unbiased mass spectrometry-based protein (PTM) analysis of M-NVs 
(Figure 6A). In brief, we investigated an informatic approach to identify PTM pattern changes with 
the requirement of select PTM enrichment that could be identified using discovery-based proteomic 
data. The ability to identify protein modifications that are both known and novel, shows that this 
unique informatic PTM approach has the capability to elucidate a greater depth of identification 
within mass spectrometry discovery datasets, and allow unique insights into the area of protein 
modification and EV biology.  
For global identification of PTMs, M-NVs and exosomes were searched using a denovo based 
database search engine optimized for PTM detection, BSI PEAKS initially, and subsequently with 
MaxQuant for protein and PTM identifications against 11 selected protein modifications. For this, 
individual MaxQuant searches were performed with each distinct modification as well as variable 
modifications. Using this strategy, 1,829 modified proteins were identified and 1,033 of these were 
quantified and comparable between the two groups based on Hierarchical clustering analysis, 
indicating similarity and variance between protein PTM abundance in M-NVs and exosomes (Figure 
6B). 
 
Between both M-NVs and exosomes, the most commonly identified protein modifications were 
deamidation of asparagine (N) (22% total) and glutamine (Q) (19% total) (Figure 6C) 
(Supplementary Tables 2-4). Deamidation is usually associated with protein degradation and 
aggregation 
[46]
 but have also been suggested to be associated with regulation of the DNA damage 
response 
[47]
. Deamidation has also been suggested as a result of reactive oxygen species reacting with 
proteins, as have oxidation of methionine 
[48]
 and carbamylation have been linked to enhance the 
generation of reactive oxygen species 
[49]
. Deamidation of asparagine is a frequent modification 
occurring as a spontaneous non-enzymatic reaction 
[50]
. This modification is associated with protein 
degradation 
[51]
, and apoptosis in cancer cells 
[52]
. Further, deamidation modifications are often 
observed in the analysis of mass spectrometry data 
[53]
, suggested to result as a consequence of sample 
preparation which can introduce deamidation 
[54]
, yet as samples are treated equally, the chance of 
significantly regulated artefactual deamination should be limited.  
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We next aimed to identify select PTMs enriched in M-NVs in comparison to exosomes. Importantly, 
216 individual modified proteins were found significantly differentially expressed (21% of total 
comparable) (student’s t-test followed by the Benjamini-Hochberg post-doc procedure, adjusted p-
value ≤ 0.05, fold change ≥ 2), while 111 protein PTMs were uniquely identified (6% of total 
identified) in either M-NVs or exosomes.  An important finding was that both known and novel 
modifications were found to be differentially expressed in M-NVs and exosomes. For enriched 
protein PTMs in M-NVs, oxidation of methionine (M) (5% total), phosphorylation of serine (S) (2% 
total), ubiquitination of lysine (K) (8% total), thiophosphorylation of threonine (T) (6% total) and 
pyroglutamic acid from glutamine (Pyro-glu from Q) (22% total) modifications were predominantly 
identified beside deamidation (NQ) (Figure 6C). These included two known phosphorylation sites 
(HSPB1 S.82, SPTN1 S.2072) 
[55, 56]
 and several proteins with ubiquitination sites, including proteins 
known to be involved in exosomes biogenesis, cargo selection, and trafficking (YWHAZ K.49, 
SDCBP S.205) 
[57, 58]
. This is the first report of ubiquitination of SDCBP site S.205. Further, we report 
ubiquitination of RS27A K.6 and PSMC6 K.369, previously described to be involved in biological 
processes such as PTMs of proteins and proteolytic activities, respectively 
[59-62]
. In M-NVs there was 
a unique enrichment of the thiophosphorylation protein modification, in addition to most proteins with 
pyroglutamic acid from glutamine. Of interest was the thiophosphorylated protein, α-synuclein, which 
is involved in protein aggregation and neurodegenerative disorders 
[63]
. The aggregation of α-
synuclein  into mature fibrillar structures is dependent on NAC region spanning residues 61-95 
[64]
. In 
our study we report thiophosphorylation on residue 81, however the functional implications of this 
modification in M-NVs remains to be investigated.  
 
In exosomes, we report phosphorylation (3% total), ubiquitination (2% total), N-terminal protein 
acetylation (5% total) and methylation (6% total) as determined by automated assignment and high 
statistical score for site specific assignment (Figure 6C). Specifically, significantly upregulated 
protein phosphorylation sites were identified for HIST1H1B T.4, RPN1 T.39, and SERPINH1 S.53 
and Y.55. 
[65]
. Further, two proteins with ubiquitination sites were identified, including the known 
(VDAC1 K.266) and novel (SCPDH S.208) modifications. Protein N-terminal acetylation and 
methylation were also identified upregulated in exosomes in comparison to M-NVs. Interestingly, 
several proteins with methylation modifications in exosomes were associated with RNA binding 
(FSCN1, GANAB, HS90A, RL9 and RS19) 
[66]
. We report differential protein and protein 
modifications between  exosomes and M-NVs, including significantly enriched ubiquitination of 
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YWHAZ K.49, PSMC6 K.369 and SDCBP S.205 in M-NVs, while the proteins were significantly 
upregulated in  exosomes. These findings suggest that proteins with and without modifications are 
distinct between  exosomes and M-NVs, highlighting the potential for deubiquitination in exosomal 
cargo sorting or targeted for inclusion in M-NVs.  
 
Taken together, our unique informatics approach to catalog protein PTMs in M-NVs demonstrated the 
prevalence of deamidation of asparagine (N) and glutamine (Q) in both M-NVs and exosomes. In 
exosomes, we report enrichment of protein modifications associated with phosphorylation, 
ubiquitination, and acetylation, consistent with previous reports of these modifications in vesicle 
biology and trafficking 
[67, 68]
. Furthermore, our study revealed differences in protein phosphorylation, 
ubiquitination, and thiophosphorylation among M-NVs, as distinct from exosomes. The functional 
implications and the reason behind these differences in protein modifications present in M-NVs 
remains an outstanding question. 
 
The potential value of exosomes as a therapeutic delivery vehicle is increasingly promising, and for 
many, the safety and feasibility has been demonstrated in clinical trials 
[69-71]
. However, such utility is 
hampered by complexity, heterogeneity, spontaneous packaging of cargo, production yield of 
different cells type, cost and timeframe in producing sufficient exosomes for downstream application. 
Furthermore, as exosomes are endosomally derived vesicles, they are enriched in proteins involved in 
intracellular assembly and trafficking such as Rab GTPases, annexin and HSP70 which may not be 
crucial for therapeutic application. Using EV characterization methods and proteomic profiling, this 
current study provided an insight into M-NVs proteome which is unique from exosomes. Our 
approach reveals that M-NVs contain distinct proteins associated with protein transport and proteins 
found at the cell surface in comparison to exosomes. Further, characterization of protein PTMs of M-
NVs highlight unique insight into these important protein-specific changes relative to exosomes. 
Future steps will include the utility of this information to develop reconfigurable therapeutic systems 
with multiple cell lines. While this study utilized only one cell line, further proteomics analysis of M-
NVs generated from different cells could provide further validation of the protein composition of M-
NVs, which subsequently could be used for better understanding of M-NVs fusion, uptake as well as 
in vitro and in vivo trafficking to further generate engineered M-NVs. 
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FIGURE LEGENDS 
 
Figure 1. Schematic diagram representing the work flow used to generate and isolate M-NVs 
and exosomes 
(A) Experimental workflow used to generate and isolate M-NVs and exosomes (Exos). SH-SY5Y (1.2 
 10
8
) cells were resuspended in DPBS and serially extruded through 10, 5 and 1 μm membranes by 
an Avanti-mini extruder. The extruded cell-derived vesicles were loaded on to an OptiPrep™ gradient 
and centrifuged at 100,000 g for 2 h. Subsequently, F6 was collected and considered as M-NVs 
following characterization.  (B) The conditioned media was collected from each flask and centrifuged 
at 2000 g for 10 min to remove cell debris. The supernatant centrifuged at 10,000 g for 30 min at 4° C  
to remove microvesicles. The resultant supernatant was centrifuged at 100,000 g for 70 min at 4° C  to 
pellet Exos. Washing step was carried out by resuspending Exos with DPBS and centrifuged at 
100,000 g for 70 min at 4° C. 
 
Figure 2. Biophysical characterization of exosomes and M-NVs 
(A) Nanoparticle tracking analysis of Exos and M-NVs highlight size (diameter) distribution and a 
mode of 179 nm for Exos and 186 nm for M-NVs (N=4). (B) Transmission electron microscopy 
reveal Exos and M-NVs with intact lipid bilayer. Scale bar, 500 nm. (C) M-NVs and Exos particle 
counts and protein concentration was normalized to total cell number (N=4). 
 
Figure 3. Proteomic profiling of cells, exosomes and M-NVs 
(A)  Silver staining of cells, Exos and M-NVs reveal similar and distinct protein profile differences. 
(B) Western blot analysis of exosomal and non exosomal proteins. (C) Discovery-based proteomic 
profiling, analysed by nLC-MS/MS, was performed for M-NVs, Exos and parental cells. Venn 
diagram showing the number of proteins identified with FDR of 1% (protein/peptide level) (N=4, 
N=2); a total of 4,269 proteins were identified in all sample types, with 1,887 common (∼44% of all 
identified proteins) and 19 and 65 proteins uniquely identified in M-NVs and Exos, respectively. (D) 
Principal component analysis of global proteome for each individual biological and technical replicate 
for each sample set, highlighting similarity in M-NVs and parental cell profiles, as distinct from Exos. 
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Figure 4. M-NVs contain distinct proteome to exosomes 
(A) Hierarchical clustering of protein expression between M-NVs and Exos. (B) Volcano 
plot showing quantitative difference of protein expression between M-NVs and Exos 
using adjusted p-value>0.05 (-log10 = 1.3) and a 2-fold difference (log2=±1). (C) Gene 
ontology (GO) enrichment annotation based on molecular function and biological 
process between M-NVs and Exos.  
 
Figure 5. Heat map of proteins within GO associated functions in exosomes and M-NVs  
Heat map of significantly enriched and shared (commonly expressed) proteins from quantitative mass 
spectrometry analysis of Exos and M-NVs, based on Z-scored label-free quantification (LFQ) values 
(biological N=4 replicates). These enriched protein subsets were correlated with GO enrichment 
annotation based on molecular function and biological process between M-NVs and Exos. The 
percentage of proteins that are represented in each set of GO functions are indicated between Exos 
versus M-NVs. 
 
Figure 6. Distinct protein PTMs profiles in M-NVs compared to exosomes 
(A) Informatic workflow used for global identification of PTMs from M-NVs and Exos. Data was 
searched using PEAKS and MaxQuant for protein and PTM identifications against 11 known protein 
modifications as variable modifications. (B) Hierarchical clustering analysis, indicating similarity and 
variance between protein PTM abundance in M-NVs and Exos. (C) Z-score normalized ratio profile 
and distribution visualization of enriched PTMs using adjusted p-value>0.05 (-log10 = 1.3) and a 2-
fold difference (log2=±1). 
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SUPPLEMENTARY DATA 
 
Supplementary Figure S1 
M-NVs purification using OptiPrep
TM
 density gradient separation. SH-SY5Y (1.2  10
8
 cells) 
were resuspended in DPBS and serially extruded through 10, 5 and 1 μm membranes by an Avanti-
mini extruder. The extruded cell-derived vesicles were loaded on to an OptiPrep™ gradient and 
centrifuged at 100,000 g for 2 h. Subsequently, all fractions (F1-F7) were isolated and 40 L for each 
fraction separated by SDS-PAGE and stained with Coomassie Blue. F6 was considered as mimetic-
NVs. 
 
Supplementary Table 1.  
Overview of proteins identified in M-NVs, Exos, and parental cells including the unique proteins 
identified in M-NVs, Exos and cells, respectively. 
 
Supplementary Table 2.  
Overview of the PTMs found significantly regulated in M-NV compared to the Exos. The 
regulation is shown in log2. p-value, which correspond to the adjusted p-value from student’s t-test 
using the Benjamini-Hochberg post-doc procedure. *p<0.05, **p<01, (-) not calculated. MaxQ = 
Found by MaxQuant (and PEAKS) NF = Not found by MaxQuant, NS = Not searched in MaxQuant. 
Numbers are literature references: 
[59, 65, 72-78]
 shown in cases with dimethylation and 
triphosphorylations, where methylation or phosphorylation is found in literature on site respectively.  
 
Supplementary Table 3.  
Overview of the PTMs regulation on proteins found enriched in M-NV. The regulation is shown 
in log2. p-value, which correspond to the adjusted p-value from student’s t-test using the Benjamini-
Hochberg post-doc procedure. *p<0.05, **p<01, (-) not calculated. 
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Supplementary Table 4.  
Overview of the PTMs regulation on proteins found enriched in Exos. The regulation is shown in 
log2. p-value, which correspond to the adjusted p-value from student’s t-test using the Benjamini-
Hochberg post-doc procedure. *p<0.05, **p<01, (-) not calculated. 
 
 
 
Table 1. Enriched top 100 in M-NVs 
Protein 
Accession 
Entry name Gene Protein names 
P42166 LAP2A_HUMAN TMPO Lamina-associated polypeptide 2, isoform alpha (Thymopoietin isoform alpha) (TP alpha) 
(Thymopoietin-related peptide isoform alpha) (TPRP isoform alpha) [Cleaved into: Thymopoietin 
(TP) (Splenin); Thymopentin (TP5)] 
P42167 LAP2B_HUMAN TMPO Lamina-associated polypeptide 2, isoforms beta/gamma (Thymopoietin, isoforms beta/gamma) (TP 
beta/gamma) (Thymopoietin-related peptide isoforms beta/gamma) (TPRP isoforms beta/gamma) 
[Cleaved into: Thymopoietin (TP) (Splenin); Thymopentin (TP5)] 
P38159 RBMX_HUMAN RBMX RNA-binding motif protein, X chromosome (Glycoprotein p43) (Heterogeneous nuclear 
ribonucleoprotein G) (hnRNP G) [Cleaved into: RNA-binding motif protein, X chromosome, N-
terminally processed] 
Q9Y6C9 MTCH2_HUMAN MTCH2 Mitochondrial carrier homolog 2 (Met-induced mitochondrial protein) 
Q9NS69 TOM22_HUMAN TOMM22 Mitochondrial import receptor subunit TOM22 homolog (hTom22) (1C9-2) (Translocase of outer 
membrane 22 kDa subunit homolog) 
P28331 NDUS1_HUMAN NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) 
(Complex I-75kD) (CI-75kD) 
Q13423 NNTM_HUMAN NNT NAD(P) transhydrogenase, mitochondrial (EC 1.6.1.2) (Nicotinamide nucleotide transhydrogenase) 
(Pyridine nucleotide transhydrogenase) 
P22695 QCR2_HUMAN UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial (Complex III subunit 2) (Core protein II) 
(Ubiquinol-cytochrome-c reductase complex core protein 2) 
Q6NUK1 SCMC1_HUMAN SLC25A24 Calcium-binding mitochondrial carrier protein SCaMC-1 (Mitochondrial ATP-Mg/Pi carrier protein 1) 
(Mitochondrial Ca(2+)-dependent solute carrier protein 1) (Small calcium-binding mitochondrial 
carrier protein 1) (Solute carrier family 25 member 24) 
P20674 COX5A_HUMAN COX5A Cytochrome c oxidase subunit 5A, mitochondrial (Cytochrome c oxidase polypeptide Va) 
O95202 LETM1_HUMAN LETM1 Mitochondrial proton/calcium exchanger protein (Leucine zipper-EF-hand-containing 
transmembrane protein 1) 
Q9BWM7 SFXN3_HUMAN SFXN3 Sideroflexin-3 
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P14854 CX6B1_HUMAN COX6B1 Cytochrome c oxidase subunit 6B1 (Cytochrome c oxidase subunit VIb isoform 1) (COX VIb-1) 
Q8IXI1 MIRO2_HUMAN RHOT2 Mitochondrial Rho GTPase 2 (MIRO-2) (hMiro-2) (EC 3.6.5.-) (Ras homolog gene family member T2) 
O75306 NDUS2_HUMAN NDUFS2 NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) 
(Complex I-49kD) (CI-49kD) (NADH-ubiquinone oxidoreductase 49 kDa subunit) 
P12235 ADT1_HUMAN SLC25A4 ADP/ATP translocase 1 (ADP,ATP carrier protein 1) (ADP,ATP carrier protein, heart/skeletal muscle 
isoform T1) (Adenine nucleotide translocator 1) (ANT 1) (Solute carrier family 25 member 4) 
O94826 TOM70_HUMAN TOMM70 Mitochondrial import receptor subunit TOM70 (Mitochondrial precursor proteins import receptor) 
(Translocase of outer membrane 70 kDa subunit) (Translocase of outer mitochondrial membrane 
protein 70) 
Q9NVI7 ATD3A_HUMAN ATAD3A ATPase family AAA domain-containing protein 3A 
Q9UJS0 CMC2_HUMAN SLC25A13 Calcium-binding mitochondrial carrier protein Aralar2 (Citrin) (Mitochondrial aspartate glutamate 
carrier 2) (Solute carrier family 25 member 13) 
Q8TEM1 PO210_HUMAN NUP210 Nuclear pore membrane glycoprotein 210 (Nuclear pore protein gp210) (Nuclear envelope pore 
membrane protein POM 210) (POM210) (Nucleoporin Nup210) (Pore membrane protein of 210 
kDa) 
Q15287 RNPS1_HUMAN RNPS1 RNA-binding protein with serine-rich domain 1 (SR-related protein LDC2) 
Q9Y4W6 AFG32_HUMAN AFG3L2 AFG3-like protein 2 (EC 3.4.24.-) (Paraplegin-like protein) 
P31930 QCR1_HUMAN UQCRC1 Cytochrome b-c1 complex subunit 1, mitochondrial (Complex III subunit 1) (Core protein I) 
(Ubiquinol-cytochrome-c reductase complex core protein 1) 
Q3ZCQ8 TIM50_HUMAN TIMM50 Mitochondrial import inner membrane translocase subunit TIM50 
Q86UP2 KTN1_HUMAN KTN1 Kinectin (CG-1 antigen) (Kinesin receptor) 
Q99459 CDC5L_HUMAN CDC5L Cell division cycle 5-like protein (Cdc5-like protein) (Pombe cdc5-related protein) 
Q9Y512 SAM50_HUMAN SAMM50 Sorting and assembly machinery component 50 homolog (Transformation-related gene 3 protein) 
(TRG-3) 
Q96HS1 PGAM5_HUMAN PGAM5 Serine/threonine-protein phosphatase PGAM5, mitochondrial (EC 3.1.3.16) (Bcl-XL-binding protein 
v68) (Phosphoglycerate mutase family member 5) 
Q53H12 AGK_HUMAN AGK Acylglycerol kinase, mitochondrial (hAGK) (EC 2.7.1.107) (EC 2.7.1.94) (Multiple substrate lipid 
kinase) (HsMuLK) (MuLK) (Multi-substrate lipid kinase) 
Q9P0J0 NDUAD_HUMAN NDUFA13 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 (Cell death regulatory protein 
GRIM-19) (Complex I-B16.6) (CI-B16.6) (Gene associated with retinoic and interferon-induced 
mortality 19 protein) (GRIM-19) (Gene associated with retinoic and IFN-induced mortality 19 
protein) (NADH-ubiquinone oxidoreductase B16.6 subunit) 
Q8IY81 SPB1_HUMAN FTSJ3 pre-rRNA processing protein FTSJ3 (EC 2.1.1.-) (2'-O-ribose RNA methyltransferase SPB1 homolog) 
(Protein ftsJ homolog 3) (Putative rRNA methyltransferase 3) 
Q02978 M2OM_HUMAN SLC25A11 Mitochondrial 2-oxoglutarate/malate carrier protein (OGCP) (Solute carrier family 25 member 11) 
O95831 AIFM1_HUMAN AIFM1 Apoptosis-inducing factor 1, mitochondrial (EC 1.1.1.-) (Programmed cell death protein 8) 
P00167 CYB5_HUMAN CYB5A Cytochrome b5 (Microsomal cytochrome b5 type A) (MCB5) 
O75947 ATP5H_HUMAN ATP5H ATP synthase subunit d, mitochondrial (ATPase subunit d) 
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Q12906 ILF3_HUMAN ILF3 Interleukin enhancer-binding factor 3 (Double-stranded RNA-binding protein 76) (DRBP76) (M-
phase phosphoprotein 4) (MPP4) (Nuclear factor associated with dsRNA) (NFAR) (Nuclear factor of 
activated T-cells 90 kDa) (NF-AT-90) (Translational control protein 80) (TCP80) 
O00217 NDUS8_HUMAN NDUFS8 NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) 
(Complex I-23kD) (CI-23kD) (NADH-ubiquinone oxidoreductase 23 kDa subunit) (TYKY subunit) 
P18859 ATP5J_HUMAN ATP5J ATP synthase-coupling factor 6, mitochondrial (ATPase subunit F6) 
P08574 CY1_HUMAN CYC1 Cytochrome c1, heme protein, mitochondrial (Complex III subunit 4) (Complex III subunit IV) 
(Cytochrome b-c1 complex subunit 4) (Ubiquinol-cytochrome-c reductase complex cytochrome c1 
subunit) (Cytochrome c-1) 
P49821 NDUV1_HUMAN NDUFV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) 
(Complex I-51kD) (CI-51kD) (NADH dehydrogenase flavoprotein 1) (NADH-ubiquinone 
oxidoreductase 51 kDa subunit) 
P43304 GPDM_HUMAN GPD2 Glycerol-3-phosphate dehydrogenase, mitochondrial (GPD-M) (GPDH-M) (EC 1.1.5.3) (mtGPD) 
P56385 ATP5I_HUMAN ATP5I ATP synthase subunit e, mitochondrial (ATPase subunit e) [Cleaved into: ATP synthase subunit e, 
mitochondrial, N-terminally processed] 
Q9NVH1 DJC11_HUMAN DNAJC11 DnaJ homolog subfamily C member 11 
Q969V3 NCLN_HUMAN NCLN Nicalin (Nicastrin-like protein) 
P50416 CPT1A_HUMAN CPT1A Carnitine O-palmitoyltransferase 1, liver isoform (CPT1-L) (EC 2.3.1.21) (Carnitine O-
palmitoyltransferase I, liver isoform) (CPT I) (CPTI-L) (Carnitine palmitoyltransferase 1A) 
Q14690 RRP5_HUMAN PDCD11 Protein RRP5 homolog (NF-kappa-B-binding protein) (NFBP) (Programmed cell death protein 11) 
Q14739 LBR_HUMAN LBR Lamin-B receptor (Integral nuclear envelope inner membrane protein) (LMN2R) 
Q16795 NDUA9_HUMAN NDUFA9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial (Complex I-39kD) 
(CI-39kD) (NADH-ubiquinone oxidoreductase 39 kDa subunit) 
O95793 STAU1_HUMAN STAU1 Double-stranded RNA-binding protein Staufen homolog 1 
P52815 RM12_HUMAN MRPL12 39S ribosomal protein L12, mitochondrial (L12mt) (MRP-L12) (5c5-2) (Mitochondrial large 
ribosomal subunit protein bL12m) 
O94905 ERLN2_HUMAN ERLIN2 Erlin-2 (Endoplasmic reticulum lipid raft-associated protein 2) (Stomatin-prohibitin-flotillin-HflC/K 
domain-containing protein 2) (SPFH domain-containing protein 2) 
Q13435 SF3B2_HUMAN SF3B2 Splicing factor 3B subunit 2 (Pre-mRNA-splicing factor SF3b 145 kDa subunit) (SF3b145) 
(Spliceosome-associated protein 145) (SAP 145) 
Q53GS9 SNUT2_HUMAN USP39 U4/U6.U5 tri-snRNP-associated protein 2 (Inactive ubiquitin-specific peptidase 39) (SAD1 homolog) 
(U4/U6.U5 tri-snRNP-associated 65 kDa protein) (65K) 
O00483 NDUA4_HUMAN NDUFA4 Cytochrome c oxidase subunit NDUFA4 (Complex I-MLRQ) (CI-MLRQ) (NADH-ubiquinone 
oxidoreductase MLRQ subunit) 
P19404 NDUV2_HUMAN NDUFV2 NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) (NADH-
ubiquinone oxidoreductase 24 kDa subunit) 
Q9H3N1 TMX1_HUMAN TMX1 Thioredoxin-related transmembrane protein 1 (Thioredoxin domain-containing protein 1) 
(Transmembrane Trx-related protein) 
P18583 SON_HUMAN SON Protein SON (Bax antagonist selected in saccharomyces 1) (BASS1) (Negative regulatory element-
binding protein) (NRE-binding protein) (Protein DBP-5) (SON3) 
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Q8NBX0 SCPDL_HUMAN SCCPDH Saccharopine dehydrogenase-like oxidoreductase (EC 1.-.-.-) 
P13073 COX41_HUMAN COX4I1 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial (Cytochrome c oxidase polypeptide IV) 
(Cytochrome c oxidase subunit IV isoform 1) (COX IV-1) 
Q96CS3 FAF2_HUMAN FAF2 FAS-associated factor 2 (Protein ETEA) (UBX domain-containing protein 3B) (UBX domain-containing 
protein 8) 
P21912 SDHB_HUMAN SDHB Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial (EC 1.3.5.1) (Iron-sulfur 
subunit of complex II) (Ip) 
O95864 FADS2_HUMAN FADS2 Fatty acid desaturase 2 (EC 1.14.19.3) (Acyl-CoA 6-desaturase) (Delta(6) fatty acid desaturase) 
(D6D) (Delta(6) desaturase) (Delta-6 desaturase) 
Q16718 NDUA5_HUMAN NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 (Complex I subunit B13) 
(Complex I-13kD-B) (CI-13kD-B) (NADH-ubiquinone oxidoreductase 13 kDa-B subunit) 
O96000 NDUBA_HUMAN NDUFB10 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 (Complex I-PDSW) (CI-PDSW) 
(NADH-ubiquinone oxidoreductase PDSW subunit) 
Q15424 SAFB1_HUMAN SAFB Scaffold attachment factor B1 (SAF-B) (SAF-B1) (HSP27 estrogen response element-TATA box-
binding protein) (HSP27 ERE-TATA-binding protein) 
Q9H9B4 SFXN1_HUMAN SFXN1 Sideroflexin-1 (Tricarboxylate carrier protein) (TCC) 
Q9Y6M9 NDUB9_HUMAN NDUFB9 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9 (Complex I-B22) (CI-B22) (LYR 
motif-containing protein 3) (NADH-ubiquinone oxidoreductase B22 subunit) 
P46087 NOP2_HUMAN NOP2 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase (EC 2.1.1.-) (Nucleolar protein 1) 
(Nucleolar protein 2 homolog) (Proliferating-cell nucleolar antigen p120) (Proliferation-associated 
nucleolar protein p120) 
P10515 ODP2_HUMAN DLAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, 
mitochondrial (EC 2.3.1.12) (70 kDa mitochondrial autoantigen of primary biliary cirrhosis) (PBC) 
(Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex) (M2 antigen 
complex 70 kDa subunit) (Pyruvate dehydrogenase complex component E2) (PDC-E2) (PDCE2) 
Q8TCJ2 STT3B_HUMAN STT3B Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B (Oligosaccharyl 
transferase subunit STT3B) (STT3-B) (EC 2.4.99.18) (Source of immunodominant MHC-associated 
peptides homolog) 
Q96PK6 RBM14_HUMAN RBM14 RNA-binding protein 14 (Paraspeckle protein 2) (PSP2) (RNA-binding motif protein 14) (RRM-
containing coactivator activator/modulator) (Synaptotagmin-interacting protein) (SYT-interacting 
protein) 
P36542 ATPG_HUMAN ATP5F1C ATP synthase subunit gamma, mitochondrial (ATP synthase F1 subunit gamma) (F-ATPase gamma 
subunit) 
P55084 ECHB_HUMAN HADHB Trifunctional enzyme subunit beta, mitochondrial (TP-beta) [Includes: 3-ketoacyl-CoA thiolase (EC 
2.3.1.16) (Acetyl-CoA acyltransferase) (Beta-ketothiolase)] 
Q96A33 CCD47_HUMAN CCDC47 Coiled-coil domain-containing protein 47 
Q03701 CEBPZ_HUMAN CEBPZ CCAAT/enhancer-binding protein zeta (CCAAT-box-binding transcription factor) (CBF) (CCAAT-
binding factor) 
P10606 COX5B_HUMAN COX5B Cytochrome c oxidase subunit 5B, mitochondrial (Cytochrome c oxidase polypeptide Vb) 
Q86UE4 LYRIC_HUMAN MTDH Protein LYRIC (3D3/LYRIC) (Astrocyte elevated gene-1 protein) (AEG-1) (Lysine-rich CEACAM1 co-
isolated protein) (Metadherin) (Metastasis adhesion protein) 
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Q8NEJ9 NGDN_HUMAN NGDN Neuroguidin (Centromere accumulated nuclear protein 1) (CANu1) (EIF4E-binding protein) 
Q8TB36 GDAP1_HUMAN GDAP1 Ganglioside-induced differentiation-associated protein 1 (GDAP1) 
Q9UHA4 LTOR3_HUMAN LAMTOR3 Ragulator complex protein LAMTOR3 (Late endosomal/lysosomal adaptor and MAPK and MTOR 
activator 3) (MEK-binding partner 1) (Mp1) (Mitogen-activated protein kinase kinase 1-interacting 
protein 1) (Mitogen-activated protein kinase scaffold protein 1) 
Q9UBX3 DIC_HUMAN SLC25A10 Mitochondrial dicarboxylate carrier (Solute carrier family 25 member 10) 
P31040 SDHA_HUMAN SDHA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial (EC 1.3.5.1) 
(Flavoprotein subunit of complex II) (Fp) 
Q03252 LMNB2_HUMAN LMNB2 Lamin-B2 
P07919 QCR6_HUMAN UQCRH Cytochrome b-c1 complex subunit 6, mitochondrial (Complex III subunit 6) (Complex III subunit VIII) 
(Cytochrome c1 non-heme 11 kDa protein) (Mitochondrial hinge protein) (Ubiquinol-cytochrome c 
reductase complex 11 kDa protein) 
P28288 ABCD3_HUMAN ABCD3 ATP-binding cassette sub-family D member 3 (70 kDa peroxisomal membrane protein) (PMP70) 
Q96AG4 LRC59_HUMAN LRRC59 Leucine-rich repeat-containing protein 59 (Ribosome-binding protein p34) (p34) [Cleaved into: 
Leucine-rich repeat-containing protein 59, N-terminally processed] 
P55265 DSRAD_HUMAN ADAR Double-stranded RNA-specific adenosine deaminase (DRADA) (EC 3.5.4.37) (136 kDa double-
stranded RNA-binding protein) (p136) (Interferon-inducible protein 4) (IFI-4) (K88DSRBP) 
Q9NW13 RBM28_HUMAN RBM28 RNA-binding protein 28 (RNA-binding motif protein 28) 
P56134 ATPK_HUMAN ATP5J2 ATP synthase subunit f, mitochondrial 
O75489 NDUS3_HUMAN NDUFS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (EC 1.6.5.3) (EC 1.6.99.3) 
(Complex I-30kD) (CI-30kD) (NADH-ubiquinone oxidoreductase 30 kDa subunit) 
O14967 CLGN_HUMAN CLGN Calmegin 
O95299 NDUAA_HUMAN NDUFA10 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 10, mitochondrial (Complex I-
42kD) (CI-42kD) (NADH-ubiquinone oxidoreductase 42 kDa subunit) 
Q9Y2W1 TR150_HUMAN THRAP3 Thyroid hormone receptor-associated protein 3 (BCLAF1 and THRAP3 family member 2) (Thyroid 
hormone receptor-associated protein complex 150 kDa component) (Trap150) 
Q9P2K5 MYEF2_HUMAN MYEF2 Myelin expression factor 2 (MEF-2) (MyEF-2) (MST156) 
Q9UGP8 SEC63_HUMAN SEC63 Translocation protein SEC63 homolog 
P57105 SYJ2B_HUMAN SYNJ2BP Synaptojanin-2-binding protein (Mitochondrial outer membrane protein 25) 
P49458 SRP09_HUMAN SRP9 Signal recognition particle 9 kDa protein (SRP9) 
Q5JPE7 NOMO2_HUMAN NOMO2 Nodal modulator 2 (pM5 protein 2) 
Q00765 REEP5_HUMAN REEP5 Receptor expression-enhancing protein 5 (Polyposis locus protein 1) (Protein TB2) 
P19338 NUCL_HUMAN NCL Nucleolin (Protein C23) 
Table 2. Cell surface, plasma membrane and associated 
Protein Entry name Protein names Gene 
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Accession 
Q12797 ASPH_HUMAN Aspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta-hydroxylase) (ASP beta-
hydroxylase) (Peptide-aspartate beta-dioxygenase) 
ASPH 
P01891 1A68_HUMAN HLA class I histocompatibility antigen, A-68 alpha chain (Aw-68) (HLA class I histocompatibility 
antigen, A-28 alpha chain) (MHC class I antigen A*68) 
HLA-A 
P01892 1A02_HUMAN HLA class I histocompatibility antigen, A-2 alpha chain (MHC class I antigen A*2) HLA-A 
P04439 1A03_HUMAN HLA class I histocompatibility antigen, A-3 alpha chain (MHC class I antigen A*3) HLA-A 
P05534 1A24_HUMAN HLA class I histocompatibility antigen, A-24 alpha chain (Aw-24) (HLA class I histocompatibility 
antigen, A-9 alpha chain) (MHC class I antigen A*24) 
HLA-A 
P10314 1A32_HUMAN HLA class I histocompatibility antigen, A-32 alpha chain (MHC class I antigen A*32) HLA-A 
P10316 1A69_HUMAN HLA class I histocompatibility antigen, A-69 alpha chain (Aw-69) (HLA class I histocompatibility 
antigen, A-28 alpha chain) (MHC class I antigen A*69) 
HLA-A 
P13746 1A11_HUMAN HLA class I histocompatibility antigen, A-11 alpha chain (MHC class I antigen A*11) HLA-A 
P16188 1A30_HUMAN HLA class I histocompatibility antigen, A-30 alpha chain (MHC class I antigen A*30) HLA-A 
P16189 1A31_HUMAN HLA class I histocompatibility antigen, A-31 alpha chain (MHC class I antigen A*31) HLA-A 
P16190 1A33_HUMAN HLA class I histocompatibility antigen, A-33 alpha chain (Aw-19) (Aw-33) (MHC class I antigen 
A*33) 
HLA-A 
P18462 1A25_HUMAN HLA class I histocompatibility antigen, A-25 alpha chain (HLA class I histocompatibility antigen, A-
10 alpha chain) (MHC class I antigen A*25) 
HLA-A 
P30443 1A01_HUMAN HLA class I histocompatibility antigen, A-1 alpha chain (MHC class I antigen A*1) HLA-A 
P30447 1A23_HUMAN HLA class I histocompatibility antigen, A-23 alpha chain (HLA class I histocompatibility antigen, A-9 
alpha chain) (MHC class I antigen A*23) 
HLA-A 
P30450 1A26_HUMAN HLA class I histocompatibility antigen, A-26 alpha chain (MHC class I antigen A*26) HLA-A 
P30453 1A34_HUMAN HLA class I histocompatibility antigen, A-34 alpha chain (Aw-34) (HLA class I histocompatibility 
antigen, A-10 alpha chain) (MHC class I antigen A*34) 
HLA-A 
P30455 1A36_HUMAN HLA class I histocompatibility antigen, A-36 alpha chain (Aw-36) (MHC class I antigen A*36) HLA-A 
P30456 1A43_HUMAN HLA class I histocompatibility antigen, A-43 alpha chain (Aw-43) (MHC class I antigen A*43) HLA-A 
P30457 1A66_HUMAN HLA class I histocompatibility antigen, A-66 alpha chain (Aw-66) (HLA class I histocompatibility 
antigen, A-10 alpha chain) (MHC class I antigen A*66) 
HLA-A 
P30459 1A74_HUMAN HLA class I histocompatibility antigen, A-74 alpha chain (Aw-19) (Aw-74) (MHC class I antigen 
A*74) 
HLA-A 
P30512 1A29_HUMAN HLA class I histocompatibility antigen, A-29 alpha chain (Aw-19) (MHC class I antigen A*29) HLA-A 
Q09160 1A80_HUMAN HLA class I histocompatibility antigen, A-80 alpha chain (Aw-80) (HLA class I histocompatibility 
antigen, A-1 alpha chain) (MHC class I antigen A*80) 
HLA-A 
Q14696 MESD_HUMAN LRP chaperone MESD (LDLR chaperone MESD) (Mesoderm development LRP chaperone MESD) 
(Mesoderm development candidate 2) (Mesoderm development protein) (Renal carcinoma 
antigen NY-REN-61) 
MESD 
Q6P1M0 S27A4_HUMAN Long-chain fatty acid transport protein 4 (FATP-4) (Fatty acid transport protein 4) (EC 6.2.1.-) SLC27A4 
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(Solute carrier family 27 member 4) 
Q9Y2Q0 AT8A1_HUMAN Phospholipid-transporting ATPase IA (EC 3.6.3.1) (ATPase class I type 8A member 1) (Chromaffin 
granule ATPase II) (P4-ATPase flippase complex alpha subunit ATP8A1) 
ATP8A1 
Q86YS7 C2CD5_HUMAN C2 domain-containing protein 5 (C2 domain-containing phosphoprotein of 138 kDa) C2CD5 
Q8ND76 CCNY_HUMAN Cyclin-Y (Cyc-Y) (Cyclin box protein 1) (Cyclin fold protein 1) (cyclin-X) CCNY 
P10909 CLUS_HUMAN Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) (Apo-J) (Complement cytolysis 
inhibitor) (CLI) (Complement-associated protein SP-40,40) (Ku70-binding protein 1) (NA1/NA2) 
(Testosterone-repressed prostate message 2) (TRPM-2) [Cleaved into: Clusterin beta chain 
(ApoJalpha) (Complement cytolysis inhibitor a chain); Clusterin alpha chain (ApoJbeta) 
(Complement cytolysis inhibitor b chain)] 
CLU 
Q8N144 CXD3_HUMAN Gap junction delta-3 protein (Connexin-31.9) (Cx31.9) (Gap junction alpha-11 protein) (Gap 
junction chi-1 protein) 
GJD3 
P54652 HSP72_HUMAN Heat shock-related 70 kDa protein 2 (Heat shock 70 kDa protein 2) HSPA2 
P23229 ITA6_HUMAN Integrin alpha-6 (CD49 antigen-like family member F) (VLA-6) (CD antigen CD49f) [Cleaved into: 
Integrin alpha-6 heavy chain; Integrin alpha-6 light chain; Processed integrin alpha-6 (Alpha6p)] 
ITGA6 
P08582 TRFM_HUMAN Melanotransferrin (Melanoma-associated antigen p97) (CD antigen CD228) MELTF 
Q99755 PI51A_HUMAN Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1-alpha) (PtdIns(4)P-5-kinase 1 
alpha) (EC 2.7.1.68) (68 kDa type I phosphatidylinositol 4-phosphate 5-kinase alpha) 
(Phosphatidylinositol 4-phosphate 5-kinase type I alpha) (PIP5KIalpha) 
PIP5K1A 
Q9H0T7 RAB17_HUMAN Ras-related protein Rab-17 RAB17 
P08183 MDR1_HUMAN Multidrug resistance protein 1 (EC 3.6.3.44) (ATP-binding cassette sub-family B member 1) (P-
glycoprotein 1) (CD antigen CD243) 
ABCB1 
O14672 ADA10_HUMAN Disintegrin and metalloproteinase domain-containing protein 10 (ADAM 10) (EC 3.4.24.81) 
(CDw156) (Kuzbanian protein homolog) (Mammalian disintegrin-metalloprotease) (CD antigen 
CD156c) 
ADAM10 
P78536 ADA17_HUMAN Disintegrin and metalloproteinase domain-containing protein 17 (ADAM 17) (EC 3.4.24.86) (Snake 
venom-like protease) (TNF-alpha convertase) (TNF-alpha-converting enzyme) (CD antigen CD156b) 
ADAM17 
Q12904 AIMP1_HUMAN Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (Multisynthase complex 
auxiliary component p43) [Cleaved into: Endothelial monocyte-activating polypeptide 2 (EMAP-2) 
(Endothelial monocyte-activating polypeptide II) (EMAP-II) (Small inducible cytokine subfamily E 
member 1)] 
AIMP1 
Q4KMQ2 ANO6_HUMAN Anoctamin-6 (Small-conductance calcium-activated nonselective cation channel) (SCAN channel) 
(Transmembrane protein 16F) 
ANO6 
P07355 ANXA2_HUMAN Annexin A2 (Annexin II) (Annexin-2) (Calpactin I heavy chain) (Calpactin-1 heavy chain) 
(Chromobindin-8) (Lipocortin II) (Placental anticoagulant protein IV) (PAP-IV) (Protein I) (p36) 
ANXA2 
Q9HDC9 APMAP_HUMAN Adipocyte plasma membrane-associated protein (Protein BSCv) APMAP 
P05023 AT1A1_HUMAN Sodium/potassium-transporting ATPase subunit alpha-1 (Na(+)/K(+) ATPase alpha-1 subunit) (EC 
3.6.3.9) (Sodium pump subunit alpha-1) 
ATP1A1 
P13637 AT1A3_HUMAN Sodium/potassium-transporting ATPase subunit alpha-3 (Na(+)/K(+) ATPase alpha-3 subunit) (EC 
3.6.3.9) (Na(+)/K(+) ATPase alpha(III) subunit) (Sodium pump subunit alpha-3) 
ATP1A3 
P05026 AT1B1_HUMAN Sodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependent ATPase ATP1B1 
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subunit beta-1) 
P54709 AT1B3_HUMAN Sodium/potassium-transporting ATPase subunit beta-3 (Sodium/potassium-dependent ATPase 
subunit beta-3) (ATPB-3) (CD antigen CD298) 
ATP1B3 
P06576 ATPB_HUMAN ATP synthase subunit beta, mitochondrial (EC 3.6.3.14) (ATP synthase F1 subunit beta) ATP5F1B 
Q04656 ATP7A_HUMAN Copper-transporting ATPase 1 (EC 3.6.3.54) (Copper pump 1) (Menkes disease-associated protein) ATP7A 
P35613 BASI_HUMAN Basigin (5F7) (Collagenase stimulatory factor) (Extracellular matrix metalloproteinase inducer) 
(EMMPRIN) (Leukocyte activation antigen M6) (OK blood group antigen) (Tumor cell-derived 
collagenase stimulatory factor) (TCSF) (CD antigen CD147) 
BSG 
Q07021 C1QBP_HUMAN Complement component 1 Q subcomponent-binding protein, mitochondrial (ASF/SF2-associated 
protein p32) (Glycoprotein gC1qBP) (C1qBP) (Hyaluronan-binding protein 1) (Mitochondrial matrix 
protein p32) (gC1q-R protein) (p33) 
C1QBP 
P27797 CALR_HUMAN Calreticulin (CRP55) (Calregulin) (Endoplasmic reticulum resident protein 60) (ERp60) (HACBP) 
(grp60) 
CALR 
O15484 CAN5_HUMAN Calpain-5 (EC 3.4.22.-) (Calpain htra-3) (New calpain 3) (nCL-3) CAPN5 
P48509 CD151_HUMAN CD151 antigen (GP27) (Membrane glycoprotein SFA-1) (Platelet-endothelial tetraspan antigen 3) 
(PETA-3) (Tetraspanin-24) (Tspan-24) (CD antigen CD151) 
CD151 
P13987 CD59_HUMAN CD59 glycoprotein (1F5 antigen) (20 kDa homologous restriction factor) (HRF-20) (HRF20) (MAC-
inhibitory protein) (MAC-IP) (MEM43 antigen) (Membrane attack complex inhibition factor) 
(MACIF) (Membrane inhibitor of reactive lysis) (MIRL) (Protectin) (CD antigen CD59) 
CD59 
P08962 CD63_HUMAN CD63 antigen (Granulophysin) (Lysosomal-associated membrane protein 3) (LAMP-3) (Melanoma-
associated antigen ME491) (OMA81H) (Ocular melanoma-associated antigen) (Tetraspanin-30) 
(Tspan-30) (CD antigen CD63) 
CD63 
P60953 CDC42_HUMAN Cell division control protein 42 homolog (G25K GTP-binding protein) CDC42 
P19022 CADH2_HUMAN Cadherin-2 (CDw325) (Neural cadherin) (N-cadherin) (CD antigen CD325) CDH2 
Q99653 CHP1_HUMAN Calcineurin B homologous protein 1 (Calcineurin B-like protein) (Calcium-binding protein CHP) 
(Calcium-binding protein p22) (EF-hand calcium-binding domain-containing protein p22) 
CHP1 
P32297 ACHA3_HUMAN Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 
Q9NY35 CLDN1_HUMAN Claudin domain-containing protein 1 (Membrane protein GENX-3745) CLDND1 
Q9Y696 CLIC4_HUMAN Chloride intracellular channel protein 4 (Intracellular chloride ion channel protein p64H1) CLIC4 
Q00610 CLH1_HUMAN Clathrin heavy chain 1 (Clathrin heavy chain on chromosome 17) (CLH-17) CLTC 
P78310 CXAR_HUMAN Coxsackievirus and adenovirus receptor (CAR) (hCAR) (CVB3-binding protein) (Coxsackievirus B-
adenovirus receptor) (HCVADR) 
CXADR 
O95886 DLGP3_HUMAN Disks large-associated protein 3 (DAP-3) (PSD-95/SAP90-binding protein 3) (SAP90/PSD-95-
associated protein 3) (SAPAP3) 
DLGAP3 
Q12959 DLG1_HUMAN Disks large homolog 1 (Synapse-associated protein 97) (SAP-97) (SAP97) (hDlg) DLG1 
P00533 EGFR_HUMAN Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-
protein kinase erbB-1) 
EGFR 
P06733 ENOA_HUMAN Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (C-myc promoter-binding 
protein) (Enolase 1) (MBP-1) (MPB-1) (Non-neural enolase) (NNE) (Phosphopyruvate hydratase) 
ENO1 
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(Plasminogen-binding protein) 
P30040 ERP29_HUMAN Endoplasmic reticulum resident protein 29 (ERp29) (Endoplasmic reticulum resident protein 28) 
(ERp28) (Endoplasmic reticulum resident protein 31) (ERp31) 
ERP29 
Q9BS26 ERP44_HUMAN Endoplasmic reticulum resident protein 44 (ER protein 44) (ERp44) (Thioredoxin domain-
containing protein 4) 
ERP44 
Q96A65 EXOC4_HUMAN Exocyst complex component 4 (Exocyst complex component Sec8) EXOC4 
P15311 EZRI_HUMAN Ezrin (Cytovillin) (Villin-2) (p81) EZR 
Q9H0  4 F234A_HUMAN Protein FAM234A (Protein ITFG3) FAM234A 
Q96AC1 FERM2_HUMAN Fermitin family homolog 2 (Kindlin-2) (Mitogen-inducible gene 2 protein) (MIG-2) (Pleckstrin 
homology domain-containing family C member 1) (PH domain-containing family C member 1) 
FERMT2 
P63096 GNAI1_HUMAN Guanine nucleotide-binding protein G(i) subunit alpha-1 (Adenylate cyclase-inhibiting G alpha 
protein) 
GNAI1 
P08754 GNAI3_HUMAN Guanine nucleotide-binding protein G(k) subunit alpha (G(i) alpha-3) GNAI3 
P00505 AATM_HUMAN Aspartate aminotransferase, mitochondrial (mAspAT) (EC 2.6.1.1) (EC 2.6.1.7) (Fatty acid-binding 
protein) (FABP-1) (Glutamate oxaloacetate transaminase 2) (Kynurenine aminotransferase 4) 
(Kynurenine aminotransferase IV) (Kynurenine--oxoglutarate transaminase 4) (Kynurenine--
oxoglutarate transaminase IV) (Plasma membrane-associated fatty acid-binding protein) (FABPpm) 
(Transaminase A) 
GOT2 
Q8TCT9 HM13_HUMAN Minor histocompatibility antigen H13 (EC 3.4.23.-) (Intramembrane protease 1) (IMP-1) (IMPAS-1) 
(hIMP1) (Presenilin-like protein 3) (Signal peptide peptidase) 
HM13 
P09429 HMGB1_HUMAN High mobility group protein B1 (High mobility group protein 1) (HMG-1) HMGB1 
Q00839 HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U (hnRNP U) (GRIP120) (Nuclear p120 
ribonucleoprotein) (Scaffold-attachment factor A) (SAF-A) (p120) (pp120) 
HNRNPU 
P08238 HS90B_HUMAN Heat shock protein HSP 90-beta (HSP 90) (Heat shock 84 kDa) (HSP 84) (HSP84) HSP90AB1 
P11021 BIP_HUMAN Endoplasmic reticulum chaperone BiP (EC 3.6.4.10) (78 kDa glucose-regulated protein) (GRP-78) 
(Binding-immunoglobulin protein) (BiP) (Heat shock protein 70 family protein 5) (HSP70 family 
protein 5) (Heat shock protein family A member 5) (Immunoglobulin heavy chain-binding protein) 
HSPA5 
P10809 CH60_HUMAN 60 kDa heat shock protein, mitochondrial (EC 3.6.4.9) (60 kDa chaperonin) (Chaperonin 60) 
(CPN60) (Heat shock protein 60) (HSP-60) (Hsp60) (HuCHA60) (Mitochondrial matrix protein P1) 
(P60 lymphocyte protein) 
HSPD1 
P11717 MPRI_HUMAN Cation-independent mannose-6-phosphate receptor (CI Man-6-P receptor) (CI-MPR) (M6PR) (300 
kDa mannose 6-phosphate receptor) (MPR 300) (Insulin-like growth factor 2 receptor) (Insulin-like 
growth factor II receptor) (IGF-II receptor) (M6P/IGF2 receptor) (M6P/IGF2R) (CD antigen CD222) 
IGF2R 
O75054 IGSF3_HUMAN Immunoglobulin superfamily member 3 (IgSF3) (Glu-Trp-Ile EWI motif-containing protein 3) (EWI-
3) 
IGSF3 
P46940 IQGA1_HUMAN Ras GTPase-activating-like protein IQGAP1 (p195) IQGAP1 
Q6UXK2 ISLR2_HUMAN Immunoglobulin superfamily containing leucine-rich repeat protein 2 (Leucine-rich repeat domain 
and immunoglobulin domain-containing axon extension protein) 
ISLR2 
P56199 ITA1_HUMAN Integrin alpha-1 (CD49 antigen-like family member A) (Laminin and collagen receptor) (VLA-1) (CD 
antigen CD49a) 
ITGA1 
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P17301 ITA2_HUMAN Integrin alpha-2 (CD49 antigen-like family member B) (Collagen receptor) (Platelet membrane 
glycoprotein Ia) (GPIa) (VLA-2 subunit alpha) (CD antigen CD49b) 
ITGA2 
P06756 ITAV_HUMAN Integrin alpha-V (Vitronectin receptor) (Vitronectin receptor subunit alpha) (CD antigen CD51) 
[Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain] 
ITGAV 
P05556 ITB1_HUMAN Integrin beta-1 (Fibronectin receptor subunit beta) (Glycoprotein IIa) (GPIIA) (VLA-4 subunit beta) 
(CD antigen CD29) 
ITGB1 
Q12809 KCNH2_HUMAN Potassium voltage-gated channel subfamily H member 2 (Eag homolog) (Ether-a-go-go-related 
gene potassium channel 1) (ERG-1) (Eag-related protein 1) (Ether-a-go-go-related protein 1) (H-
ERG) (hERG-1) (hERG1) (Voltage-gated potassium channel subunit Kv11.1) 
KCNH2 
P32004 L1CAM_HUMAN Neural cell adhesion molecule L1 (N-CAM-L1) (NCAM-L1) (CD antigen CD171) L1CAM 
P09382 LEG1_HUMAN Galectin-1 (Gal-1) (14 kDa laminin-binding protein) (HLBP14) (14 kDa lectin) (Beta-galactoside-
binding lectin L-14-I) (Galaptin) (HBL) (HPL) (Lactose-binding lectin 1) (Lectin galactoside-binding 
soluble 1) (Putative MAPK-activating protein PM12) (S-Lac lectin 1) 
LGALS1 
Q9NUP9 LIN7C_HUMAN Protein lin-7 homolog C (Lin-7C) (Mammalian lin-seven protein 3) (MALS-3) (Vertebrate lin-7 
homolog 3) (Veli-3) 
LIN7C 
Q15334 L2GL1_HUMAN Lethal(2) giant larvae protein homolog 1 (LLGL) (DLG4) (Hugl-1) (Human homolog to the D-lgl gene 
protein) 
LLGL1 
Q12907 LMAN2_HUMAN Vesicular integral-membrane protein VIP36 (Glycoprotein GP36b) (Lectin mannose-binding 2) 
(Vesicular integral-membrane protein 36) (VIP36) 
LMAN2 
Q8IWT6 LRC8A_HUMAN Volume-regulated anion channel subunit LRRC8A (Leucine-rich repeat-containing protein 8A) 
(Swelling protein 1) 
LRRC8A 
P14174 MIF_HUMAN Macrophage migration inhibitory factor (MIF) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) (L-
dopachrome isomerase) (L-dopachrome tautomerase) (EC 5.3.3.12) (Phenylpyruvate tautomerase) 
MIF 
O95297 MPZL1_HUMAN Myelin protein zero-like protein 1 (Protein zero-related) MPZL1 
O00159 MYO1C_HUMAN Unconventional myosin-Ic (Myosin I beta) (MMI-beta) (MMIb) MYO1C 
P54920 SNAA_HUMAN Alpha-soluble NSF attachment protein (SNAP-alpha) (N-ethylmaleimide-sensitive factor 
attachment protein alpha) 
NAPA 
P13591 NCAM1_HUMAN Neural cell adhesion molecule 1 (N-CAM-1) (NCAM-1) (CD antigen CD56) NCAM1 
Q9H4L5 OSBL3_HUMAN Oxysterol-binding protein-related protein 3 (ORP-3) (OSBP-related protein 3) OSBPL3 
O75781 PALM_HUMAN Paralemmin-1 (Paralemmin) PALM 
P09619 PGFRB_HUMAN Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta 
platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) 
(CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD 
antigen CD140b) 
PDGFRB 
P30101 PDIA3_HUMAN Protein disulfide-isomerase A3 (EC 5.3.4.1) (58 kDa glucose-regulated protein) (58 kDa microsomal 
protein) (p58) (Disulfide isomerase ER-60) (Endoplasmic reticulum resident protein 57) (ER protein 
57) (ERp57) (Endoplasmic reticulum resident protein 60) (ER protein 60) (ERp60) 
PDIA3 
P13667 PDIA4_HUMAN Protein disulfide-isomerase A4 (EC 5.3.4.1) (Endoplasmic reticulum resident protein 70) (ER 
protein 70) (ERp70) (Endoplasmic reticulum resident protein 72) (ER protein 72) (ERp-72) (ERp72) 
PDIA4 
P35232 PHB_HUMAN Prohibitin PHB 
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Q99623 PHB2_HUMAN Prohibitin-2 (B-cell receptor-associated protein BAP37) (D-prohibitin) (Repressor of estrogen 
receptor activity) 
PHB2 
Q13492 PICAL_HUMAN Phosphatidylinositol-binding clathrin assembly protein (Clathrin assembly lymphoid myeloid 
leukemia protein) 
PICALM 
P98161 PKD1_HUMAN Polycystin-1 (PC1) (Autosomal dominant polycystic kidney disease 1 protein) PKD1 
Q15139 KPCD1_HUMAN Serine/threonine-protein kinase D1 (EC 2.7.11.13) (Protein kinase C mu type) (Protein kinase D) 
(nPKC-D1) (nPKC-mu) 
PRKD1 
Q9NRY6 PLS3_HUMAN Phospholipid scramblase 3 (PL scramblase 3) (Ca(2+)-dependent phospholipid scramblase 3) PLSCR3 
O15031 PLXB2_HUMAN Plexin-B2 (MM1) PLXNB2 
P49768 PSN1_HUMAN Presenilin-1 (PS-1) (EC 3.4.23.-) (Protein S182) [Cleaved into: Presenilin-1 NTF subunit; Presenilin-1 
CTF subunit; Presenilin-1 CTF12 (PS1-CTF12)] 
PSEN1 
Q9P2B2 FPRP_HUMAN Prostaglandin F2 receptor negative regulator (CD9 partner 1) (CD9P-1) (Glu-Trp-Ile EWI motif-
containing protein F) (EWI-F) (Prostaglandin F2-alpha receptor regulatory protein) (Prostaglandin 
F2-alpha receptor-associated protein) (CD antigen CD315) 
PTGFRN 
P15151 PVR_HUMAN Poliovirus receptor (Nectin-like protein 5) (NECL-5) (CD antigen CD155) PVR 
P61026 RAB10_HUMAN Ras-related protein Rab-10 RAB10 
P51153 RAB13_HUMAN Ras-related protein Rab-13 (Cell growth-inhibiting gene 4 protein) RAB13 
Q9NP72 RAB18_HUMAN Ras-related protein Rab-18 RAB18 
Q15286 RAB35_HUMAN Ras-related protein Rab-35 (GTP-binding protein RAY) (Ras-related protein Rab-1C) RAB35 
P20339 RAB5A_HUMAN Ras-related protein Rab-5A RAB5A 
P61006 RAB8A_HUMAN Ras-related protein Rab-8A (Oncogene c-mel) RAB8A 
P63000 RAC1_HUMAN Ras-related C3 botulinum toxin substrate 1 (Cell migration-inducing gene 5 protein) (Ras-like 
protein TC25) (p21-Rac1) 
RAC1 
P60763 RAC3_HUMAN Ras-related C3 botulinum toxin substrate 3 (p21-Rac3) RAC3 
P11233 RALA_HUMAN Ras-related protein Ral-A RALA 
P35241 RADI_HUMAN Radixin RDX 
O15258 RER1_HUMAN Protein RER1 RER1 
P61586 RHOA_HUMAN Transforming protein RhoA (Rho cDNA clone 12) (h12) RHOA 
P08134 RHOC_HUMAN Rho-related GTP-binding protein RhoC (Rho cDNA clone 9) (h9) RHOC 
Q01974 ROR2_HUMAN Tyrosine-protein kinase transmembrane receptor ROR2 (EC 2.7.10.1) (Neurotrophic tyrosine 
kinase, receptor-related 2) 
ROR2 
P62070 RRAS2_HUMAN Ras-related protein R-Ras2 (Ras-like protein TC21) (Teratocarcinoma oncogene) RRAS2 
Q14108 SCRB2_HUMAN Lysosome membrane protein 2 (85 kDa lysosomal membrane sialoglycoprotein) (LGP85) (CD36 
antigen-like 2) (Lysosome membrane protein II) (LIMP II) (Scavenger receptor class B member 2) 
(CD antigen CD36) 
SCARB2 
P18827 SDC1_HUMAN Syndecan-1 (SYND1) (CD antigen CD138) SDC1 
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P53985 MOT1_HUMAN Monocarboxylate transporter 1 (MCT 1) (Solute carrier family 16 member 1) SLC16A1 
P43007 SATT_HUMAN Neutral amino acid transporter A (Alanine/serine/cysteine/threonine transporter 1) (ASCT-1) 
(SATT) (Solute carrier family 1 member 4) 
SLC1A4 
Q15758 AAAT_HUMAN Neutral amino acid transporter B(0) (ATB(0)) (Baboon M7 virus receptor) (RD114/simian type D 
retrovirus receptor) (Sodium-dependent neutral amino acid transporter type 2) (Solute carrier 
family 1 member 5) 
SLC1A5 
P08195 4F2_HUMAN 4F2 cell-surface antigen heavy chain (4F2hc) (4F2 heavy chain antigen) (Lymphocyte activation 
antigen 4F2 large subunit) (Solute carrier family 3 member 2) (CD antigen CD98) 
SLC3A2 
P23975 SC6A2_HUMAN Sodium-dependent noradrenaline transporter (Norepinephrine transporter) (NET) (Solute carrier 
family 6 member 2) 
SLC6A2 
O14745 NHRF1_HUMAN Na(+)/H(+) exchange regulatory cofactor NHE-RF1 (NHERF-1) (Ezrin-radixin-moesin-binding 
phosphoprotein 50) (EBP50) (Regulatory cofactor of Na(+)/H(+) exchanger) (Sodium-hydrogen 
exchanger regulatory factor 1) (Solute carrier family 9 isoform A3 regulatory factor 1) 
SLC9A3R1 
P60880 SNP25_HUMAN Synaptosomal-associated protein 25 (SNAP-25) (Super protein) (SUP) (Synaptosomal-associated 25 
kDa protein) 
SNAP25 
Q99523 SORT_HUMAN Sortilin (100 kDa NT receptor) (Glycoprotein 95) (Gp95) (Neurotensin receptor 3) (NT3) (NTR3) SORT1 
P12931 SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src (EC 2.7.10.2) (Proto-oncogene c-Src) (pp60c-src) (p60-
Src) 
SRC 
Q12846 STX4_HUMAN Syntaxin-4 (Renal carcinoma antigen NY-REN-31) STX4 
O15400 STX7_HUMAN Syntaxin-7 STX7 
Q9Y4C2 TCAF1_HUMAN TRPM8 channel-associated factor 1 (TRP channel-associated factor 1) TCAF1 
P02786 TFR1_HUMAN Transferrin receptor protein 1 (TR) (TfR) (TfR1) (Trfr) (T9) (p90) (CD antigen CD71) [Cleaved into: 
Transferrin receptor protein 1, serum form (sTfR)] 
TFRC 
P04216 THY1_HUMAN Thy-1 membrane glycoprotein (CDw90) (Thy-1 antigen) (CD antigen CD90) THY1 
Q9Y490 TLN1_HUMAN Talin-1 TLN1 
P49755 TMEDA_HUMAN Transmembrane emp24 domain-containing protein 10 (21 kDa transmembrane-trafficking protein) 
(S31III125) (S31I125) (Tmp-21-I) (Transmembrane protein Tmp21) (p23) (p24 family protein delta-
1) (p24delta1) (p24delta) 
TMED10 
Q9H813 TM206_HUMAN Transmembrane protein 206 TMEM206 
Q96JJ7 TMX3_HUMAN Protein disulfide-isomerase TMX3 (EC 5.3.4.1) (Thioredoxin domain-containing protein 10) 
(Thioredoxin-related transmembrane protein 3) 
TMX3 
Q13641 TPBG_HUMAN Trophoblast glycoprotein (5T4 oncofetal antigen) (5T4 oncofetal trophoblast glycoprotein) (5T4 
oncotrophoblast glycoprotein) (M6P1) (Wnt-activated inhibitory factor 1) (WAIF1) 
TPBG 
Q8NG11 TSN14_HUMAN Tetraspanin-14 (Tspan-14) (DC-TM4F2) (Transmembrane 4 superfamily member 14) TSPAN14 
P54578 UBP14_HUMAN Ubiquitin carboxyl-terminal hydrolase 14 (EC 3.4.19.12) (Deubiquitinating enzyme 14) (Ubiquitin 
thioesterase 14) (Ubiquitin-specific-processing protease 14) 
USP14 
Q15836 VAMP3_HUMAN Vesicle-associated membrane protein 3 (VAMP-3) (Cellubrevin) (CEB) (Synaptobrevin-3) VAMP3 
P51809 VAMP7_HUMAN Vesicle-associated membrane protein 7 (VAMP-7) (Synaptobrevin-like protein 1) (Tetanus-
insensitive VAMP) (Ti-VAMP) 
VAMP7 
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Q9P0L0 VAPA_HUMAN Vesicle-associated membrane protein-associated protein A (VAMP-A) (VAMP-associated protein A) 
(VAP-A) (33 kDa VAMP-associated protein) (VAP-33) 
VAPA 
P21796 VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 (VDAC-1) (hVDAC1) (Outer mitochondrial 
membrane protein porin 1) (Plasmalemmal porin) (Porin 31HL) (Porin 31HM) 
VDAC1 
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